We market and commercialize specialty care and rare disease products
Inceptua has a very experienced commercialization team, with a patient centric approach. Our core competence is to successfully bring specialty, rare disease, and orphan drugs to the market. Our team puts equal focus on commercial, medical and market access, securing the holistic approach needed to succeed. We have a strong infrastructure, local presence, and expertise covering Europe and the Middle East.
Inceptua in-license or partner late stage assets or commercial stage products. Our partnership models are flexible and the structure depends on the strategic objectives of our partners.
Jetrea is a truncated form of human plasmin and is a first-in-class pharmacological vitreolysis therapy approved to treat patients with symptomatic vitreomacular adhesion or vitreomacular traction.
Farydak (panobinostat) is a prescription oral medication used in combination with proteasome inhibitors and corticosteroids to treat patients with relapsed or refractory multiple myeloma who have received prior treatments.
Click on 'Read More' below to access the press release: Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe
Our team is engaged, entrepreneurial, and patient centric, with a long track record bringing products to the market. With our significant experience of different partnership models, we are open for traditional in-licensing as well as flexible distribution set-ups. Our adaptable approach allows us to work with tailored partnership solutions that best support the needs of our partners and their mid- to long-term objectives.
Ask our experts